ATE518011T1 - Erhöhte expression von t- zellenrezeptorvermittelter tumornekrosefaktorsuperfamilie und chemokin-mrna in peripheren blut leukozyten bei patienten mit morbus& xa;crohn - Google Patents

Erhöhte expression von t- zellenrezeptorvermittelter tumornekrosefaktorsuperfamilie und chemokin-mrna in peripheren blut leukozyten bei patienten mit morbus& xa;crohn

Info

Publication number
ATE518011T1
ATE518011T1 AT07755012T AT07755012T ATE518011T1 AT E518011 T1 ATE518011 T1 AT E518011T1 AT 07755012 T AT07755012 T AT 07755012T AT 07755012 T AT07755012 T AT 07755012T AT E518011 T1 ATE518011 T1 AT E518011T1
Authority
AT
Austria
Prior art keywords
disease
crohn
patients
peripheral blood
cell receptor
Prior art date
Application number
AT07755012T
Other languages
English (en)
Inventor
Masato Mitsuhashi
Stephan Targan
Original Assignee
Hitachi Chemical Co Ltd
Hitachi Chemical Res Ct Inc
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hitachi Chemical Co Ltd, Hitachi Chemical Res Ct Inc, Cedars Sinai Medical Center filed Critical Hitachi Chemical Co Ltd
Application granted granted Critical
Publication of ATE518011T1 publication Critical patent/ATE518011T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT07755012T 2006-04-07 2007-04-05 Erhöhte expression von t- zellenrezeptorvermittelter tumornekrosefaktorsuperfamilie und chemokin-mrna in peripheren blut leukozyten bei patienten mit morbus& xa;crohn ATE518011T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79035406P 2006-04-07 2006-04-07
PCT/US2007/008597 WO2007117611A2 (en) 2006-04-07 2007-04-05 Enhanced t cell receptor-mediated tumor necrosis factor superfamily and chemokine mrna expression in peripheral blood leukocytes in patients with crohn's disease

Publications (1)

Publication Number Publication Date
ATE518011T1 true ATE518011T1 (de) 2011-08-15

Family

ID=38581650

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07755012T ATE518011T1 (de) 2006-04-07 2007-04-05 Erhöhte expression von t- zellenrezeptorvermittelter tumornekrosefaktorsuperfamilie und chemokin-mrna in peripheren blut leukozyten bei patienten mit morbus& xa;crohn

Country Status (6)

Country Link
US (1) US7838239B2 (de)
EP (1) EP2005175B1 (de)
JP (1) JP5027209B2 (de)
CN (1) CN101410714A (de)
AT (1) ATE518011T1 (de)
WO (1) WO2007117611A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008503206A (ja) * 2004-05-25 2008-02-07 日立化成工業株式会社 癌感受性を測定する方法
CN101044249B (zh) * 2004-10-20 2012-09-05 日立化成工业株式会社 通过定量mRNA定制给药的方法
WO2008109782A2 (en) * 2007-03-06 2008-09-12 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease in children
US12110555B2 (en) 2004-12-08 2024-10-08 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease
US11268149B2 (en) 2004-12-08 2022-03-08 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease
US10544459B2 (en) 2004-12-08 2020-01-28 Cedars-Sinai Medical Center Methods of using genetic variants for the diagnosis and treatment of inflammatory bowel disease
ATE512234T1 (de) * 2005-04-28 2011-06-15 Hitachi Chemical Res Ct Inc Ex-vivo-genexpression in vollblut als modell für die beurteilung von individueller variation gegenüber nahrungszusätzen
DE102006051628A1 (de) 2006-11-02 2008-05-08 Daimler Ag Abgasturbolader für eine Brennkraftmaschine
WO2008116150A2 (en) 2007-03-21 2008-09-25 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (ipaa) factors in the treatment of inflammatory bowel disease
EP2056110A1 (de) * 2007-10-31 2009-05-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Biomarker zur Vorhersage einer Reaktionsfähigkeit auf eine Anti-TNF-alpha-Behandlung
JP2011502535A (ja) 2007-11-14 2011-01-27 日立化成工業株式会社 末梢血白血球における、Fc受容体を介した腫瘍壊死因子スーパーファミリーmRNA発現
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
US9580752B2 (en) 2008-12-24 2017-02-28 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
BR112013011242A2 (pt) * 2010-11-11 2016-11-01 Nestec S A Ch cápsula, máquina de produção de bebidas e sistema para a preparação de um produto nutricional
US9902996B2 (en) 2011-02-11 2018-02-27 Cedars-Sinai Medical Center Methods of predicting the need for surgery in crohn's disease
EP2734233B1 (de) * 2011-07-18 2017-11-01 Hitachi Chemical Co., Ltd. Verfahren zur vorhersage des ansprechens eines wirtes auf krebsimmuntherapien durch ex-vivo-induktion von mit leukozytenfunktionen assoziierten mrnas
KR20230109779A (ko) 2013-03-27 2023-07-20 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한섬유증 및 염증의 완화 및 반전
EP3022295A4 (de) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signatur des tl1a (tnfsf15)-signalweges
CN103865998B (zh) * 2013-12-16 2016-04-20 周菊华 一种肿瘤免疫治疗效果的基因检测方法
US20150257586A1 (en) * 2014-03-11 2015-09-17 Starbucks Corporation Dba Starbucks Coffee Company Single-serve beverage production machine
DE112016003948T5 (de) 2015-08-31 2018-05-09 City Of Sapporo Molekulare verfahren zum beurteilen einer urothelialen erkrankung
KR20240095481A (ko) 2016-03-17 2024-06-25 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법
AU2020275413A1 (en) 2019-05-14 2021-12-23 Cedars-Sinai Medical Center TL1A patient selection methods, systems, and devices

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925572A (en) * 1987-10-20 1990-05-15 Pall Corporation Device and method for depletion of the leukocyte content of blood and blood components
US4880548A (en) * 1988-02-17 1989-11-14 Pall Corporation Device and method for separating leucocytes from platelet concentrate
US5210015A (en) * 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US5491063A (en) * 1994-09-01 1996-02-13 Hoffmann-La Roche Inc. Methods for in-solution quenching of fluorescently labeled oligonucleotide probes
DE69739909D1 (de) * 1996-03-26 2010-07-29 Michael S Kopreski Methoden aus plasma oder serum extrahierte extrazelluraere rna zur diagnoseüberwachung oder evaluation von krebs verwenden
US5683698A (en) * 1996-08-02 1997-11-04 New England Deaconess Hospital Formulation for alleviating symptoms associated with arthritis
US7514232B2 (en) * 1996-12-06 2009-04-07 Becton, Dickinson And Company Method for detecting T cell response to specific antigens in whole blood
US6183951B1 (en) * 1997-04-11 2001-02-06 Prometheus Laboratories, Inc. Methods of diagnosing clinical subtypes of crohn's disease with characteristic responsiveness to anti-Th1 cytokine therapy
US20020006613A1 (en) * 1998-01-20 2002-01-17 Shyjan Andrew W. Methods and compositions for the identification and assessment of cancer therapies
AU768189B2 (en) 1999-06-15 2003-12-04 Nutri-Logics, Inc. Nutrient formulations for disease reduction, and related treatment and component screening methods
US6692916B2 (en) * 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US20020048566A1 (en) * 2000-09-14 2002-04-25 El-Deiry Wafik S. Modulation of cellular apoptosis and methods for treating cancer
ATE480618T1 (de) * 2000-10-31 2010-09-15 Hitachi Chemical Res Ct Inc Methode für das sammeln und das verwenden von kern-mrna
US20020182274A1 (en) 2001-03-21 2002-12-05 Kung-Ming Lu Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract
US6905827B2 (en) * 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US6964850B2 (en) 2001-11-09 2005-11-15 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US7767390B2 (en) * 2001-11-20 2010-08-03 Oncomedx, Inc. Methods for evaluating drug-resistance gene expression in the cancer patient
US7871619B2 (en) 2001-11-30 2011-01-18 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
FI20020078A7 (fi) 2002-01-15 2003-07-16 Danisco Immuunijärjestelmän stimulointi polydextroosilla
US6878518B2 (en) * 2002-01-22 2005-04-12 The Trustees Of The University Of Pennsylvania Methods for determining steroid responsiveness
US7745180B2 (en) * 2002-04-24 2010-06-29 Hitachi Chemical Co., Ltd. Device and method for high-throughput quantification of mRNA from whole blood
AU2003232872A1 (en) 2002-05-27 2003-12-12 Ostergotlands Lans Landsting Method for determining immune system affecting compounds
AU2002953533A0 (en) * 2002-12-24 2003-01-16 Arthron Limited Fc receptor modulating compounds and compositions
JP2008503206A (ja) * 2004-05-25 2008-02-07 日立化成工業株式会社 癌感受性を測定する方法
EP1875246B1 (de) 2005-04-15 2016-10-05 CanImGuide Therapeutics AB Diagnoseverfahren zum nachweis von krebs durch messen der menge eines cytokinähnlichen il-6
ATE512234T1 (de) 2005-04-28 2011-06-15 Hitachi Chemical Res Ct Inc Ex-vivo-genexpression in vollblut als modell für die beurteilung von individueller variation gegenüber nahrungszusätzen
EP1945814A2 (de) * 2005-09-27 2008-07-23 Source MDX Erstellung von genexpressionsprofilen zur identifizierung , beobachtung und behandlung rheumatoider arthritis
US20100190162A1 (en) 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease

Also Published As

Publication number Publication date
EP2005175A2 (de) 2008-12-24
JP5027209B2 (ja) 2012-09-19
EP2005175B1 (de) 2011-07-27
US7838239B2 (en) 2010-11-23
CN101410714A (zh) 2009-04-15
JP2009535016A (ja) 2009-10-01
WO2007117611A3 (en) 2008-08-07
WO2007117611A2 (en) 2007-10-18
EP2005175A4 (de) 2009-06-03
US20090253133A1 (en) 2009-10-08

Similar Documents

Publication Publication Date Title
ATE518011T1 (de) Erhöhte expression von t- zellenrezeptorvermittelter tumornekrosefaktorsuperfamilie und chemokin-mrna in peripheren blut leukozyten bei patienten mit morbus& xa;crohn
ATE473781T1 (de) Gerät zum nachweis von arrhythmie in einem medizinprodukt
WO2006133420A3 (en) Treatment of patients with cancer therapy
DE602007009483D1 (de) Vorrichtung zur erkennung und behandlung von depressionen
AU2003295644A8 (en) Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
WO2004053066A3 (en) Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy
ATE448732T1 (de) Sammlung von informationen zur aktivität und schlafqualität mit einem medizinprodukt
ATE432693T1 (de) Kombinationstherapie zur behandlung von diabetes und dadurch bedingten leiden sowie zur behandlung von mittels erhöhung des glp-1-spiegels im blut verbesserten leiden
NO996229D0 (no) Heparanase spesifikke molekylaere prober og deres anvendelse i forskning og medisin
DE602007011062D1 (de) Biofeedback-system und anzeigevorrichtung
ATE333921T1 (de) Defibrillatoren angepasst an vorgesehene patienten
WO2003079887A3 (en) Measuring blood flow rate or cardiac output
WO2009070442A3 (en) Fc receptor-mediated tumor necrosis factor superfamily mrna expression in peripheral blood leukocytes
ATE442592T1 (de) Detektion und/oder beobachtung von synuclein- assoziierten krankheiten
WO2009064973A3 (en) Diagnostic kits and methods for scd or sca therapy selection
DE60037116D1 (de) System zur behandlung eines patienten mit einem medikament zur optimierung der therapie und zur verhinderung eines negativen nebeneffektes
ATE356994T1 (de) Screeningverfahren mit pim1-kinase oder pim3- kinase
CN108814570A (zh) 一种理疗仪及参数确定方法
DE602005017241D1 (de) Behandlung von Gewichtsverlust bei Patienten mit entzündlichen Darmerkrankungen mittels S. boulardii
EP1742643A4 (de) Modulation der glukose-6-phosphatase-translokase-expression
WO2007117589A3 (en) Enhanced fc receptor-mediated tumor necrosis factor superfamily and chemokine mrna expression in peripheral blood leukocytes in patients with rheumatoid arthritis
RU2008116567A (ru) Биомаркеры
Mabilleau et al. Number of circulating CD14-positive cells and the serum levels of TNF-α are raised in acute charcot foot
DE602004031706D1 (de) Extracorporeale Photopherese kombiniert mit anti-TNF Behandlung
WO2006047475A3 (en) Detection and analysis of ophthalmically-relevant fluorescent molecules

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties